Safety and Efficacy Study of LIPO-202 for the Reduction of Central Abdominal Bulging in Obese Subjects

Completed · Phase 2 · Has a placebo group

Conditions studied: Central Abdominal Bulging

In brief

This is a multi-center, randomized, placebo-controlled, double-blind study evaluating the safety and efficacy of LIPO-202 for the reduction of central abdominal bulging in obese subjects.

Key facts

Study ID

NCT02568319

Run by

Neothetics, Inc

People needed

120

Starts

2015-09-01

Last updated by the study team

2015-12-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Healthy male or non-pregnant female subjects
• Capable of providing written consent
• BMI > 30 kg/m2 but < 40 kg/m2
• Stable diet and exercise routine
• At least "Slightly Dissatisfied" with their abdominal bulging on the Abdominal Contour Questionnaire (ACQ)

You may not qualify if…

• BMI > 40 kg/m2
• Have had any treatment of the fat around your abdomen, including surgical procedures (tummy tuck, liposuction), injections for fat loss or treatments with devices to reduce fat in your abdomen.
• Plan on starting a weight loss or exercise program during the study
• Known hypersensitivity to study drugs
• Have any medical condition that might complicate study procedures

Where it is running

• Diagnamics, Inc. — Encinitas, California, United States
• Ablon Skin Institute and Research Center — Manhattan Beach, California, United States
• The Center for Clinical & Cosmetic Research — Aventura, Florida, United States
• Skin Research Institute — Coral Gables, Florida, United States
• Tennessee Clinical Research Center — Nashville, Tennessee, United States
• Charlottesville Medical Research Center — Charlottesville, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.